BioSpace News Archive

Cambridge and Stevenage, United Kingdom, 30 June 2022 / NRG Therapeutics Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, and Domainex Ltd., today announce a collaboration focused on developing novel small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), today announced the launch of the PREVENT (a Prospective multi-canceR Early-detection and interVENTional) study, China’s first prospective interventional study to evaluate the performance of Burning Rock’s early cancer detection test, OverC™, in the asymptomatic population.

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier , all resolutions were duly passed on a show of hands.

On Tuesday, the U.S. Food and Drug Administration’s independent experts on the Vaccines and Related Biological Products Advisory Committee met to publicly discuss whether a change to the current vaccine strain composition of COVID-19 vaccines for booster doses is necessary for the 2022 fall and winter seasons.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the impact factor of its journal Clinical Chemistry has risen to 12.167 in the 2021 Clarivate Journal Citation Reports.

Xoran Technologies announced the company’s recent submission of an FDA 510(k) application for TRON™, an open-bore fluoroscopy computed tomography (CT) for full-body point-of-care imaging.

Biovica, active in cancer diagnostics, announces that the company’s CFO and deputy CEO Cecilia Driving today has submitted her letter of resignation.

Benson Hill, Inc., a food tech company unlocking the natural genetic diversity of plants, announced a revised time for its second quarter earnings call and webcast to 8 a.m. Eastern Time from 8:30 a.m. Eastern Time on Monday, Aug. 8, 2022.

Tevogen Bio announced its new Research and Development Center located in Philadelphia’s historic Wanamaker building to further expand the company’s R&D capability allowing expansion of its precision T cell product pipeline.

Retractable Technologies, Inc. announced that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.